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Objective:  To present and demonstrate a new simplified method for synthesizing results 
of multiple clinical trials in resuscitation research.  Methods:  The mean difference across 
studies in the proportion of favorable outcomes between experimental and control groups 
is calculated.  This difference is shown to have a  t-distribution.  Its significance can be 
ascertained with a simple t-test.  The analysis can be implemented in a one-page 
computer spreadsheet.  Results:  Simplified meta-analysis provides high sensitivity and 
can be extended to include weighting of studies according to size or quality, comparison 
of subgroups of studies, tests for outliers, and calculation of the power of the meta-
analysis.  Sample analyses are presented for two experimental forms of cardiopulmonary 
resuscitation: interposed abdominal compression CPR and active compression-
decompression CPR.  Conclusions:  Traditional narrative reviews, taking note of the 
proportion of individual studies with statistically significant results, can lead to erroneous 
conclusions and unnecessary delays in the clinical use of research findings.  Simplified 
meta-analysis can provide rapid, quantitative, and accurate estimates of the amount of 
benefit or harm from an experimental intervention and can further empower physicians to 
practice evidence-based medicine. 
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A key aspect of evidence-based medicine is the careful analysis of research literature 
concerning the effectiveness of a proposed novel treatment or procedure.  Traditional 
methods of research synthesis involve tabulating the available studies that are related to a 
particular treatment or innovation and noting the number of significant positive studies 
versus the number of non-significant ones.  This procedure has been termed “vote 
counting”, in which each study casts a vote for or against the innovation under 
consideration 
1-3
.  The proportion of positive studies required to justify a change in 
clinical practice may vary among reviewers and regulatory bodies.  In the usual collective 
review a positive recommendation is made when a majority, or more, of trials are 
statistically significant.  If there are equal numbers of statistically significant and non-
significant clinical studies, many reviewers will conclude the vote to be a draw and 




The vote counting approach to research review is now known to lead systematically to 
high percentages of erroneous conclusions
1-3
.  In particular, vote counting produces Type 
II statistical errors or false negative evaluations—that is, erroneously accepting the null 
hypothesis when the results of treatment are quite genuine
2, 4
.  Conventional testing for 
statistical significance minimizes the probability of Type I errors or false positive 
evaluations—that is, erroneously concluding there is a real treatment effect when the 
results are due to sampling variability.  However, consideration of conventional statistical 
significance does not protect against Type II errors. 
 
Meta-analysis, defined as the quantitative synthesis of data from multiple clinical studies, 
minimizes both Type I and Type II errors.  This approach is gaining popularity as an 
alternative to vote counting
5-11
.  The present paper introduces a simple and user-friendly 
form of meta-analysis for use by groups of physicians and others seeking to set evidence-
based practice guidelines.  It is an extension and simplification of the “observed minus 
expected” (O-E) approach of Yusuf and Peto5, 12, combined with the concept of 
cumulative meta-analysis introduced by Lau
6
.  This simplified approach to meta-analysis 
has a number of advantages for systematic overviews of clinical trials. 
 
1. The method is derived easily from fundamental principles and can be understood, 
verified, and trusted by physicians with knowledge of elementary statistics as taught 
in universities and medical schools.  It is designed to demystify meta-analysis and to 
place control of the technical aspects of the process directly in the hands of clinical 
decision-makers.  These decision makers can then combine clinical judgment with 
statistical inference to arrive at the best possible decisions about the timely adoption 
of new methods reported in the research literature. 
 
2. It is easily performed.  All that is needed is a basic spreadsheet program such as 
Microsoft Excel.  Given a spreadsheet template, one can perform the technical 
computations for a meta-analysis about as easily as making a table of results from a 
literature survey.  Special purpose software is not required. 
 
 2 
3. It allows for a variety of optional calculations.  These include the number needed to 
treat (or harm), the weighting of studies according to their size, quality, or category, a 
procedure for detecting outliers, calculation of the power of the meta-analysis, and 
easy comparison of subgroups of studies. 
 






Suppose that one reviews a series of  m  randomized clinical trials and that in each trial 
an experimental group is compared with a control group and survival is the principle 
outcome measure.  The proposed method focuses upon the differences in the proportions 
of survivors (or other favorable outcomes) in each study, which is denoted p.  To say 
“the experimental treatment increased survival by 15 percent,” is to say p = 0.15.  Any 
dichotomous outcome measure, indicating either benefit or harm, may be used in the 
place of survival.  These might include the occurrence of tumor response, death, stroke, a 
significant cardiac event, the development of lung cancer, graft patency after one year, 
etc.  If some studies measure harm (e.g. mortality) rather than benefit (e.g. survival), it is 
a simple matter to recast results in terms of the proportions of patients with favorable 
outcomes, so that the direction of the results is consistent for all studies. 
 
 
2.1 Testing the mean difference in outcome 
 
Let 1p  be the proportion of favorable outcomes in a control group of 1n  patients.  Let 2p  
be the proportion of favorable outcomes in an experimental group of 2n  patients.  Let the 
corresponding values i2i1i2i1 n,n,p,p  represent results of the  i-th  study in a series of  m  
studies to be synthesized, and let i1i2i ppp   be the difference in the proportions of 
favorable outcomes observed in the  i-th  study.  Definitions of these and related variables 









m Number of studies in a series of studies to be 
analyzed 
n Number of patients in a study group 
p Measured proportion of survivors in a control 
group or an experimental group 
p Difference in proportions of survivors 
(experimental – control) 
s(X) Standard deviation of random variable, X 
s
2
(X) Variance of random variable, X 
w Optional weighting factor for a particular study 
W Sum of weighting factors for all studies in a 
series to be analyzed 
Subscripts  
1 Control group 
2 Experimental group 
i, j Any single study in series of studies 
 
 
The s'p i1 , s'p i2 , and s'p i  are random variables that depend upon the true probabilities 
of favorable outcome in the various experimental and control groups and also upon 
sampling variability.  Suppose that each trial were repeated a large number of times and 
the null hypothesis were true.  That is, there is no real treatment effect.  Then for each 
study, i, the difference in the proportions of favorable outcomes, i2i1i ppp  , 



















 .       (1) 
 
Expression (1) is based upon the principle that the variance of a sum or difference of 
independent random variables equals the sum of the variances
13
.  The control and 
experimental results are independent, because they come from different patients.  The 





 for the measured proportions of survivors in the 
control and experimental groups are unbiased, as shown in Appendix 1.  All data needed 
to evaluate expression (1) are readily obtained from published results. 
 
Assume initially that the studies to be synthesized are given equal weights.  (Use of 
unequal weights, based for example upon study quality or size, is discussed in the next 
 4 
section, 2.2.)  The test statistic to be used in meta-analysis is the mean difference in 








.        (2) 
 
Under the null hypothesis the expected value of p  is zero.  Again, since the variance of 
a sum or difference of such independent random variables is the sum of the variances
13
, 

















.      (3) 
 
Thus  ps2   is easily calculated from the 2121 n,n,p,p  data for the various studies.  







 .          (4) 
 
One can show, along the lines of Welch
14
, that this test statistic is distributed very much 
like a “Student” t-distribution with a number of degrees of freedom roughly equal to 
twice the total number of survivors in all of the studies to be synthesized
 *




i1i1 npnp2df  

.  Note that a t-distribution with more than about 
50 degrees of freedom is equivalent to the normal distribution.  Thus for all most meta-
analyses one can simply use the normal distribution. 
 
To construct 95% confidence intervals for p , let t97.5 be the 97.5
th
 percentile of the t-
distribution with  df  degrees of freedom, as found in standard tables or functions.  
Typically this value is close to 2.0.  For the normal distribution t97.5 = 1.96.  The 95 
percent confidence interval for p  is    5.97tpsp  .  If this confidence interval 
includes zero, one cannot reject the null hypothesis that p  = 0 at the P = 0.05 level.  If 
the confidence interval does not include zero, there is a significant positive or negative 
effect of treatment across studies. 
 
                                                   
*
 A slightly better approximation can be obtained using the formula df = 2S(1+3(S/N)), where S is the total 
number of survivors in all studies and N is the total number of patients in all studies.  If a majority of 




2.2 Optional features of the analysis 
 
Weighting of studies.  In expression (2) p  is an un-weighted average, to which all 
studies contribute equally, in keeping with the recommendation of Peto, Collins and 
coworkers.
12, 15
.  If one wishes to deal with varying size or quality of the studies by 
introducing weights so that some studies contribute more to p than others, then for a 

























,    (6) 
 
and the 95% confidence interval for p  is    5.97tps  , as before. 
 
Weights may be assigned to reflect the sizes (n’s) of various studies, such that a large 
study counts for more than a smaller one.  One such approach
1, 16-18
 uses inverse variance 
estimates as a weighting factors.  In this case weights are calculated as )p(s1w i
2
i  .  
The inverse variance values are larger for larger and better-controlled studies.  This type 
of weighting is especially recommended when combining several initial small trials with 
subsequent larger trials.  Inverse variance weights produce minimum variance of the 
overall weighted average
19, 20
.  Subjective ratings of study quality can also be used as 
weights.  However, the value of reviewers’ impressionistic ratings of the quality or 




The mathematics of the present method accommodates both users who argue that unequal 
weighting of studies is arbitrary and capricious and also those who argue that equal 
weighting ignores obvious differences in study quality and size.  For reviewers of the first 
persuasion all weights are simply set to 1.0.  For reviewers of the second persuasion each 
individual study is weighted according to predetermined criteria.  The use of inverse 
variance weighting is a popular compromise strategy and is rapidly becoming standard 
practice in medical meta-analyses.  Typically, the main results of the meta-analysis will 
be insensitive to easily tested changes in the weighting method, providing evidence that 
the weights were not chosen to produce a particular result. 
 
The inclusion of weighting factors in the mathematics and in spreadsheets for performing 
the analysis also has practical advantages.  An examination of the influence of various 
individual studies upon the outcome of the meta-analysis can be done by the simple 
expedient of setting the weight of a particular study to zero.  If the significance of the 
overall analysis changes greatly, then a single study is driving the results.  By extension, 
analysis of sub-groups of studies can be performed by using non-zero weights for 
particular studies of interest and zero weights for all other studies. 
 6 
 
Subgroup comparison.  Suppose one finds among the studies in a meta-analysis two 
apparent subgroups of studies that differ in treatment effect, possibly on the basis 
differences in patient populations, treatment implementation, or clinical setting.  To test 
whether there is there a significant difference in the treatment effect between the 
subgroups one can re-do the meta-analysis twice—first setting the weights for subgroup 2 
to zero, leaving subgroup 1, and then setting the weights of subgroup 1 to zero, leaving 
subgroup 2.  If the 95% confidence intervals do not overlap and just touch at one 
common point, then the results for one subgroup will be greater than the results for the 
other subgroup at least (0.975)
2
 = 95.0625 percent of the time.  In this sense one can say 
that if the 95 percent confidence intervals of p  for mutually exclusive subgroups of 
studies do not overlap, then the subgroups are significantly different from each other.  In 
many cases of apparent differences among studies, the 95 percent confidence intervals 
will overlap
1, 3
.  Then one can avoid needless speculation over differences consistent with 
sampling variation alone.  If the 95 percent confidence interval for a subgroup of m=1 
study is clearly separated from that for the remaining m-1 studies, then the study may be 
unidentified as an outlier. 
 





.  This statistic, advocated by McQuay and Moore
23
, represents the average 
number of patients that must be given an experimental treatment to obtain one additional 
survivor (or other good outcome).  It is useful in evaluating the cost effectiveness of 
proposed innovations. 
 







  is zero, and the standard deviation of  t  is very close to 1.00, unless the 
aggregate number of survivors is very small.  In this case one can also calculate the 
power of the meta-analysis for the alternative hypothesis that the true effect is at least, 
say, a 10 percent difference in the proportion of survivors.  Then, for the alternative 




 .  The statistical power of the meta-analysis is 
the probability of making a correct positive evaluation of the experimental treatment, 
assuming the alternative hypothesis is true.  Using  P = 0.05 for significance testing, the 
power is 
 
)96.1t(F 1  ,          (7) 
 
where F is the cumulative probability density function for the standard normal 
distribution.
*
  The usefulness of computing the statistical power of a meta-analysis has 
been emphasized recently by Hedges and Pigott
24
. 
                                                   
*
 In Microsoft Excel this function is named NORMSDIST(). 
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2.3 Spreadsheets for performing meta-analysis 
 
A standard spreadsheet program such as Microsoft Excel is sufficient to perform a 
simplified meta-analysis.  In one compact format, each study is represented in a column 
of the spreadsheet.  Successive steps in the calculations are performed in successive rows 
of the spreadsheet.  Top rows include the study author, the study weight, the number of 
favorable outcomes and total number of patients in control and experimental groups.  
Subsequent rows include control and experimental group proportions, the ip  for each 





iii   for weighted study calculations.  Then p  and its 95% 
confidence limits are calculated using expressions (4), (5) and (6) together with the t-
distribution and inverse t-distribution functions.  Finally the number needed to treat and 
power of the meta-analysis are calculated.  Excel’s SUMIF(weight > 0) and 
COUNTIF(weight > 0) functions can be utilized across columns to implement a new 
cumulative meta-analyses after the appearance of each successive study.  Then each 
successive column represents a cumulative meta-analysis at one point in time.  For 
inverse variance weighting of the studies, the weights are assigned values equal to 
)p(s1 i
2  . 
 
 
3. Results—sample analyses 
 
Sample meta-analyses were performed on studies relating to two experimental techniques 
of cardiopulmonary resuscitation (CPR).  The first is the addition of interposed 
abdominal compression (IAC) to otherwise standard CPR
25-27
.  The second is CPR with 
active compression and decompression (ACD) of the chest
28-30
.  Reviews of these 




.  During IAC-CPR positive pressure is 
applied to the abdomen in counterpoint to the rhythm of chest compression, so that the 
abdomen is being compressed when chest pressure is relaxed.  During ACD-CPR 
positive and negative pressures are applied alternately to the chest by means of a 
“plunger” that forms a seal with the anterior chest wall.  Both methods improve 
hemodynamics in animal studies of electrically induced ventricular fibrillation
33, 34
.  Both 





Relevant full length, peer reviewed publications were identified using evidence 
evaluation worksheets created by the research working group of the American Heart 
Association
37, 38.  Individual trials were obtained from MEDLINE searches, the author’s 
files, and reference lists of review articles on newer techniques in resuscitation as 
referenced in
39
.  The end points analyzed include short-term survival and long-term 
survival.  Short-term survival is defined as return of spontaneous circulation (ROSC).  
Long-term survival is defined as hospital discharge with intact neurological function. 
 
Results of simplified cumulative meta-analysis for IAC-CPR are shown in Table 2 and 
Figure 1.  Results of simplified cumulative meta-analysis for ACD-CPR are shown in 
 8 
Table 3 and Figure 2.  Tables 2 and 3 were copied from a working spreadsheet, a 
template for which can be obtained from the author at no cost and modified by the user 
for similar meta-analyses.  The top rows in Tables 2 and 3 show raw data abstracted from 
individual studies.  The last five rows of Tables 2 and 3 show data for a cumulative meta-
analysis.  In these bottom rows successive columns from left to right represent successive 
stages of the cumulative meta-analysis.  The mean p -value under Study 1 describes the 
first study only.  The mean p -value under Study 2 describes the combined results of the 
first two studies.  The mean p -value under Study 3 describes the combined results of 




Table 2. Cumulative meta-analysis for ROSC and discharge survival data in studies 
of IAC-CPR.  Here studies are given inverse variance weights, 1/s2(p) 
 
  ROSC  Discharge 
         
Raw data         
Last Study ID  Mateer Ward Sack 1 Sack 2  Ward Sack 1 
Study  Weight  349.93 40.47 116.25 154.96   256.00 255.75 
Study #  1 2 3 4  2.1 3.1 
# Cont Alive  45 3 14 21  0 3 
n1  146 17 55 76  17 55 
# Exp Alive  40 6 29 33  1 8 
n2  145 16 48 67  16 48 
         
Proportions         
p1  0.3082 0.1765 0.2545 0.2763  0.0000 0.0545 
p2  0.2759 0.3750 0.6042 0.4925  0.0625 0.1667 
p  -0.0324 0.1985 0.3496 0.2162  0.0625 0.1121 
s2(p)  0.0029 0.0247 0.0086 0.0065  0.0039 0.0039 
         
Cumulative data         
p   -0.0324 0.0831 0.1719 0.1830  0.0625 0.0873 
SE p   0.0535 0.0506 0.0444 0.0389  0.0625 0.0442 
2-tail P(t)  0.5458 0.8680 0.0983 0.0062  0.4226 0.0599 
NNT  -30.9 12.0 5.8 5.5  16.0 11.5 
Power  0.46 0.51 0.61 0.73  --- 0.62 




Table 3. Cumulative meta-analysis for ROSC data in studies of ACD-CPR  
using inverse variance weights, 1/s2(p) 
 
Last Study ID C93N T94J L94J S95J1 S95J2 L96J S96J1 S96J2 S96R P97C 
           
Raw Data           
Study Weight 67.56 55.32 131.79 416.61 949.51 56.36 878.88 1761.87 221.72 557.88 
Study # 1 2 3 4 5 6 7 8 9 10 
Cont Alive 9 9 24 27 65 12 129 84 68 77 
n1 30 28 77 136 310 30 386 510 114 258 
Exp Alive 20 15 24 20 56 10 140 91 54 114 
n2 32 25 53 117 297 26 405 501 106 254 
           
Proportions           
p1 0.3000 0.3214 0.3117 0.1985 0.2097 0.4000 0.3342 0.1647 0.5965 0.2984 
p2 0.6250 0.6000 0.4528 0.1709 0.1886 0.3846 0.3457 0.1816 0.5094 0.4488 
p 0.3250 0.2786 0.1411 -0.0276 -0.0211 -0.0154 0.0115 0.0169 -0.0871 0.1504 
s2(p) 0.01480 0.01808 0.00759 0.00240 0.00105 0.01774 0.00114 0.00057 0.00451 0.00179 
           
Cumulative 
Data 
          
p  0.3250 0.3041 0.2198 0.0663 0.0151 0.0140 0.0132 0.0147 0.0097 0.0251 
SE p  0.1217 0.0902 0.0627 0.0386 0.0248 0.0244 0.0198 0.0152 0.0148 0.0140 
2-tail P(t) 0.0098 0.0011 0.0006 0.0878 0.5447 0.5657 0.5061 0.3344 0.5123 0.0732 
NNT 3.1 3.3 4.6 15.1 66.4 71.2 76.0 68.0 102.8 39.8 
Power 0.13 0.20 0.36 0.74 0.98 0.98 1.00 1.00 1.00 1.00 
           
 
 
In Table 2 the four data columns to the left represent a meta-analysis of short-term 
survival.  The two columns to the right represent a separate meta-analysis of long-term, 
discharge survival.  Studies of IAC-CPR showed a significant treatment effect for both 
short-term and long-term survival.  p  is 10.7 percent for ROSC, 8.7 percent for hospital 
discharge.  The effect of IAC is highly significant for ROSC data  
(P = 0.006) and of borderline statistical significance (P = 0.06) for discharge survival 
data.  These summary values can be immediately converted into the number-needed-to-
treat, p/1NNT  , the number of patients that must be treated to obtain one additional 
survivor
23
.  For return of spontaneous circulation the NNT is 9.  For discharge survival, 
the corresponding NNT is 12.  The last row in Table 2 demonstrates that the process of 
cumulative meta-analysis gradually increases the statistical power for detecting a true 
positive treatment effect.  Here power was calculated using expression (7) and assuming 
a true positive treatment effect of p  = 10%.  Increasing statistical power reduces the 
 10 
probability of a false negative evaluation or Type II error, which is equal to one minus 
the power. 
 
Figure 1(A) shows a cumulative meta-analysis plot for IAC-CPR to demonstrate 
historical trends with the publication of each successive study.   The top data point and its 
95 percent confidence interval represent the historically first trial, the next a combination 
of the first two trials, the third a combination of the first three, etc.  These data points 
correspond to the successive meta-analyses of ROSC data in the columns of Table 2 from 
left to right.  Statistical significance typically emerges after publication of just a few 
studies to reach a stable value.  Thereafter, the addition of further studies merely narrows 
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FIGURE 1 .  Simplified cumulative meta-analysis for IAC-CPR.  Successive 
points from top to bottom represent a separate meta-analysis after the 
appearance of each study in the series.  (A) Equal weighting: each study is 
assigned weight 1.0.  (B) Inverse variance weighting: each study is assigned 
weight , 1/s2(p).  The major conclusions of the meta-analysis are independent 
of the weighting method. 
 
 
The cumulative meta-analysis shown in Figure 1(A) was conducted with equal study 
weights in keeping with the recommendation of Peto
12
.  The corresponding cumulative 
meta-analysis in Figure 1(B) was conducted with inverse variance weights in keeping 
with the recommendation of Hedges
1, 17
.  The raw data for Figures 1(A) and 1(B) were 
identical.  For dichotomous variables such as survival, individual study variances are 
highly dependent upon group size, as indicated in Equation (1).  As expected, inverse 
variance weights diminish the impact upon the overall results of  
Study 2, which had small patient numbers.  However, the major conclusions of the meta-
analysis of IAC-CPR are insensitive to the particular weighting method used. 
 12 
 
Critics often object to one study or another on technical grounds. Because the number of 
studies in the IAC series is small, the question arises "would the analysis be significant if 
the offending study were left out?"  Table 4 shows results of meta-analysis of ROSC data 
for IAC-CPR, in terms of 95 percent the confidence limits for p  when each of the 4 
studies in turn is given zero weight in the analysis.  A zero weight has the effect of 
excluding one particular study and can be assigned very easily in a spreadsheet format by 
changing the weight value to zero.  Here the results, for inverse variance weighting, show 
that at least one of the studies by Sack, each of which included different patients, is 
needed to conclude that IAC-CPR produces more frequent ROSC than standard CPR. 
 
 
Table 4. Sensitivity testing: effects of omitting single studies upon 95% confidence 
intervals for p ; ROSC data for IAC-CPR versus standard CPR 
 
Study omitted Lower 95% limit Upper 95% limit 
   
None 0.031 0.184 
Mateer 0.152 0.375 
Ward 0.022 0.180 
Sack 1 -0.029 0.140 
Sack 2 -0.014 0.162 
 
At least one of the studies by Sack, which included different patients at different 




Retrospectively, there does appear to be a difference in the benefit of IAC-CPR between 
the three in-hospital studies and the one pre-hospital study.  A separate meta-analysis of 
the three inverse variance weighted in-hospital studies (numbers 2, 3, and 4) for ROSC 
data gives p  = 26 percent with a 95% confidence interval from 15 to 38 percent.  This 
range does not overlap the 95% confidence interval of the one pre-hospital study, which 
ranged from -14 to +7 percent.  (In the pre-hospital study patients assigned to IAC-CPR 
necessarily received some standard CPR from bystanders and also during transport to the 
hospital, perhaps diluting the effect of IAC.)  Thus for in-hospital resuscitations, one can 
conclude from the three studies that IAC-CPR roughly doubles rates of initial 
resuscitation from about 25 to about 50 percent.  For the two in-hospital studies of long-
term survival with IAC-CPR also appeared to double from about 8 to 16 percent.  
However, the total number of patients studied for long-term survival is small and the 
result is of borderline statistical significance (P = 0.06). 
 
A simplified meta-analysis of studies of ACD-CPR using equal weights for each study 
showed a statistically significant treatment effect for ROSC, with p  equal to 7.7 percent 
(data not shown).  However, when inverse variance weighting was used to emphasize the 
 13 
relative importance of larger, better-controlled studies, p  for ROSC was reduced to 2.5 
percent.  The 95% confidence interval for p  was –0.002 to 0.053, just including zero.  
For hospital discharge p  was less than 0.01 and clearly not significant.  Figure 2 shows 
a cumulative meta-analysis plot for ACD-CPR with inverse variance weights.  Here the 
pattern is unusual in that early studies show a much greater effect than do later ones, with 
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Evidently, the studies of ACD-CPR were not all cast from the same mold.  Inspection of 
the p values reveals one group of studies indicating a significant positive benefit 
(studies 1, 2, 3, and 10) and a second group having zero benefit upon survival (studies 4-
9).  The 95 percent confidence interval for p  in the first group of studies is 0.10 to 0.24.  
The 95 percent confidence interval for p  in the second group of studies is -0.03 to 
+0.03.  Although this subgroup analysis was performed retrospectively with knowledge 
of the results, the impression for the ROSC data is unmistakably bimodal and not that 
expected for a homogeneous population.  Those close to the research suggest rigorous 
training in the technique, which is physically more difficult to perform than standard 
CPR
40
, is required for good results.  Such training was clearly described in the last 
positive trial, and was probably done in the first few positive trials.  This effect cannot be 
demonstrated for long-term survival following ACD-CPR, however, which is uniformly 





Research is producing growing numbers of important innovations in healthcare generally, 
and in the field of resuscitation in particular.  However, there are often years of delay 
between achievement of positive results in valid research studies and their subsequent 
implementation in routine clinical practice
6, 41, 42
. One reason for delayed implementation 
of research findings is the excessive processing and analysis that evidence requires before 
application
41
.  Busy individual clinicians have limited time to pour over seemingly 
conflicting data.  Panels of experts meet for at most a few days to consider multiple 
practice guidelines in rapid succession with no time scheduled for seeking answers to 
questions that arise.  Overly complex statistical analysis is simply avoided by such 
panels, and conservative conclusions are drawn, often using an explicit or implicit vote-




Simpler, user-friendly techniques of research synthesis are needed to bridge the gap 
between research and practice.  Simpler techniques of meta-analysis would empower 
more physicians to practice evidence-based medicine, especially in conjunction with the 
increased availability of the necessary raw data on the Internet.  Such techniques 
implemented on laptop computers with standard software would allow guideline-writing 
groups to address a variety of "what if" questions in the process of deliberation, such as 
"what if this particular study were left out" or "what if certain high quality studies 
counted more". 
 
This paper presents an approach to meta-analysis of a series of two-group clinical trials 
that is straightforward both in theory and in execution.  The simplification of technical 
mathematics, which leads to a t-test of the overall significance of included studies, makes 
the approach personally verifiable by physician analysts.  The actual calculations require 
no more than a one-page spreadsheet.  One can create or borrow, and validate, a sample 
spreadsheet quickly.  Subsequent meta-analyses can be done easily by replacing the raw 
 15 
data in the sample spreadsheet with raw data from other studies and expanding or 
contracting the table appropriately.  Special purpose software is not needed. 
 
Assumptions of the method are few.  One is that the variance of a sum of independent or 
uncorrelated random variables equals the sum of the variances
13
.  This assumption is 
reasonable since the component p values are derived from independent studies.  (It is 
important to confirm that the same patients do not reappear in more than one study, as 
can happen with a preliminary report and a final report of an ongoing trial.)  The use of a 
t-distribution for expression (4) requires the further assumption that the average 
difference in proportions will be normally distributed.  This assumption is reasonable, 
since the component binomial distributions approach the normal distribution in shape for 
group n’s > 20 (true for all but the very smallest clinical trials)13.  As the number  m  of 
studies that are combined increases, the central limit theorem
13
 further strengthens this 
assumption.  Finally, the assumption that a normally distributed random variable, divided 
by its estimated standard deviation has a Student’s t distribution, as originally described 
by Welch
14
, is well precedented in statistics and can be confirmed for proportional data 
by numerical examples. 
 
Meta-analysis in terms of the proportional differences, ip , is especially significant for 
those assumptions that are not present.  Just as in the summed observed minus expected 
method of Yusuf, Peto, and coworkers
5
, there is no assumption of homogeneity.  The test 
statistic p  is treated simply a weighted sum of random variables.  Hence expressions (2) 
through (6) do not require that the s'p i  be similar in magnitude. 
 
The studies may vary in terms of patient populations, drug doses, procedural skills, 
hospital settings, exclusion criteria, etc.  It is not necessary to assume that the trials 
synthesized are exactly comparable—only that they test the same basic intervention as it 
might be implemented in various settings in the real world.  The s'p i  need not even 
measure proportions of exactly the same things.  One study could measure proportion of 
24-hour survivors and another study could measure the proportion of 48-hour survivors 
after the same treatment.  A reviewer might ask the question: “is there evidence of 
treatment effect upon long term survival?”  The meta-analysis combining these studies is 
perfectly valid as long as “long term” is clearly defined as 24 hours or greater.  Similarly, 
if some studies measured mortality and others measured the occurrence of stroke or 
myocardial infarction, they could be combined, as above, in a meta-analysis of clearly 
defined “major adverse outcomes” following standard vs. experimental therapy. 
 
For those accustomed to the high false negative results of traditional literature reviews 
and research synthesis
1, 3
, meta-analysis may seem to be a rush to judgment, provoking 
one or more now classical objections
3, 21
.  Each objection is a variation on the common 
theme that “you shouldn’t combine apples and oranges”.  One such concern is the 
challenge of dealing with multiple end points recorded in individual studies, such as long-
term survival (apples) and short-term survival (oranges).  Strictly speaking, ROSC and 
discharge survival data from the same studies of experimental CPR cannot be combined 
in the same simplified meta-analysis because they are not independent.  A conservative 
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and now technically easy remedy, as shown in Figures 1 and 2, is to perform a separate 
analysis for each type of end-point, even though the number of studies measuring a less 
popular or hard to obtain end point, like discharge survival, may be smaller. 
 
A second objection relates to variable methodological quality of included studies, 
although subjective quality ratings do not necessarily correlate with the size of treatment 
effects
3, 21, 22
.  Critics argue that less worthy studies (apples) should not be compared with 
more worthy studies (oranges).  This issue can also be dealt with empirically.  Should 
subjective quality ratings be available and agreed to, one can perform a separate meta-
analysis (subgroup comparison) for studies of high and low quality by alternately setting 
the weights of low and high quality studies to zero.  If the results differ, one can rely on 
the “strong” studies; if they do not, then all studies should be included3. 
 
A third objection to meta-analysis relates to variable research methods among studies 
with different patient populations, exclusion criteria, data recording methods, hospital 
settings, or other kinds of “apples and oranges”.  Again this objection can be answered 
empirically.  One may simply perform a separate meta-analysis for each class of 
studies—that is, perform a subgroup comparison.  If the 95% confidence intervals for the 
p values for two subgroups do not overlap, then one has statistical evidence for a case of 
apples and oranges.  Otherwise one only has evidence for normal sampling variation.  
Thus, all three classical objections to meta-analysis can be dealt with by doing a separate 
meta-analysis of the apples versus the oranges.  Heated philosophical debates can be 
attenuated by taking a closer look at the data. 
 
Earlier workers in the field of meta-analysis anticipated several aspects of the approach 
presented in this paper.  The method of Rosenthal and Rubin
43
 began with reported p-
values as inputs and later
16
 included differences in proportions.  The present approach 
represents a fresh look at the problem from the standpoint of the physician.  In this 
context meta-analysis is a tool that must be used in conjunction with clinical judgment.  
In the first phase of evaluation of a new intervention one is simply trying to determine if 
a proposed treatment, in general, produces an effect on survival or some other favorable 
outcome
12
.  If it does, then the effect seen in the selected trials is likely to generalize to 
the even broader range of circumstances found in widespread practice.  As more data 
become available a second phase of meta-analysis may be done to determine if a 
particular intervention produces different outcomes in particular patient groups.  The 
present method can be used to help answer both of these questions.  Simplified meta-
analysis provides a tool to distill relevant data, but, of course, it cannot substitute for 







Meta-analysis allows the reviewer to deal with the situation of multiple small studies 
having promising effects but small n’s and somewhat varying methodology, owing to 
limitations of cost, time, patient recruitment, or the inherent difficulty of resuscitation 
research.  Formal meta-analysis is immune from the systematic and excessive Type II 
errors associated with the traditional "vote-counting" methods of research synthesis
2, 4
.  
Such analysis can guide individual and institutional practice and shorten the time between 
medical research discoveries and their clinical implementation.  The method presented 
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Appendix 1: Estimating the variance of a binomial distribution from measured 
proportions. 
 
Let  p  be the measured proportion of survivors among  n  treated patients, for whom the 
true probability of survival is  .  The mean (expected value) of the binomial distribution 
of p-values is E(p) =  and the variance, V(p), of the binomial distribution is  
V(p) = (1- )/n .  It is well known that the maximum likelihood estimate of    is p 13.  
In turn, the maximum likelihood estimate of V is n/)p1(p)p(Vˆ  .  This expression 
provides an initial estimate of the binomial distribution variance. 
 
Let us check the expected value of n/)p1(p)p(Vˆ   to see if it is biased compared to 
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The initial estimate is biased by a factor of (n-1)/n.  However, if we multiply this estimate 

















is unbiased, as can be confirmed by repeating steps A1.1 through A1.4 for the new 
estimate. 
 
